Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo

Paromomycin is an aminoglycoside antibiotic approved in 2006 for the treatment of visceral leishmaniasis caused by Leishmania donovani in Southeast Asia. Although this drug is not approved for the treatment of visceral and cutaneous leishmaniasis in Brazil, it is urgent and necessary to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Coser, Elizabeth M., Ferreira, Bianca A., Branco, Nilson, Yamashiro-Kanashiro, Edite H., Lindoso, José Angelo L., Coelho, Adriano C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548989/
https://www.ncbi.nlm.nih.gov/pubmed/33011651
http://dx.doi.org/10.1016/j.ijpddr.2020.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548989/
https://www.ncbi.nlm.nih.gov/pubmed/33011651
http://dx.doi.org/10.1016/j.ijpddr.2020.08.001

Ejemplares similares